PRESS RELEASES

Date Title and Summary Additional Formats
Toggle Summary Endocyte Announces Exclusive Worldwide License of Phase 3 Ready PSMA-Targeted Radioligand Therapy for Development in Prostate Cancer
- Transformational Transaction Provides Endocyte with the Most Advanced Targeted Radioligand Therapy in Development for Prostate Cancer, Addressing a Greater than $1 Billion Market Opportunity - -  High Response Rates Demonstrated in Late Stage Prostate Cancer Patients in Clinical Data Presented at
View HTML
Toggle Summary Endocyte to Present at the 2017 Cantor Global Healthcare Conference
WEST LAFAYETTE, Ind. , Sept. 19, 2017 (GLOBE NEWSWIRE) -- Endocyte, Inc. (NASDAQ:ECYT), a leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized therapy, today announced that the company's management team will present at the 2017 Cantor
View HTML
Toggle Summary Endocyte Presents Data at the 2017 CAR-TCR Summit Further Demonstrating the Ability to Manage Cytokine Release Syndrome Related to CAR T-Cell Therapy
- Poster further demonstrates the potential of Endocyte's SMDC CAR-T platform to more safely regulate CAR-T therapy for solid tumors - - Unwanted toxicities may be controlled through the administration of approved agents - WEST LAFAYETTE, Ind. , Sept. 06, 2017 (GLOBE NEWSWIRE) -- Endocyte, Inc.
View HTML
Toggle Summary Endocyte Announces Presentation at the European Society for Medical Oncology (ESMO)
WEST LAFAYETTE, Ind. , Sept. 05, 2017 (GLOBE NEWSWIRE) -- Endocyte, Inc. (NASDAQ:ECYT), a leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized therapy, today announced that a poster will be presented at the European Society for Medical
View HTML
Toggle Summary Endocyte Announces Presentations at the 254th American Chemical Society National Meeting & Exposition
WEST LAFAYETTE, Ind. , Aug. 16, 2017 (GLOBE NEWSWIRE) -- Endocyte, Inc. (NASDAQ:ECYT), a leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized therapy, today announced that four posters will be presented by Endocyte scientists at the 254
View HTML
Toggle Summary Endocyte Reports Second Quarter Financial Results and Provides Clinical and Pipeline Update
- Plans to Initiate Clinical Development for CAR T-Cell Program in Osteosarcoma in 2018 - - Nearing Completion of Enrollment of Expansion Phase of EC1169 Trial in Prostate Cancer Patients - - IND filed for Dual-Targeted DNA Crosslinker EC2629 - - Conference Call Today at 4:30 p.m.
View HTML
Toggle Summary Endocyte Announces Second Quarter 2017 Earnings Conference Call
WEST LAFAYETTE, Ind. , Aug. 01, 2017 (GLOBE NEWSWIRE) -- Endocyte, Inc. , (NASDAQ:ECYT) announced today that the company will host a conference call on Tuesday, Aug. 8th , at 4:30 p.m. EDT to discuss its second quarter financial results and provide an operational update.
View HTML
Toggle Summary Endocyte Announces Clinical Updates for EC1456 and EC1169
- Company Continuing EC1169 Program in Taxane-Exposed Patients, but Ending Clinical Development of EC1456 and of EC1169 in Taxane-Naïve Patients -   - Refocusing Efforts on Chimeric Antigen Receptor T-cell (CAR T-cell) and Dual-Targeted DNA Crosslinker Drug EC2629 Programs - - Restructuring to
View HTML
Toggle Summary Endocyte to Announce Updated Data on EC1456 and EC1169 at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting
WEST LAFAYETTE, Ind. , May 26, 2017 (GLOBE NEWSWIRE) -- Endocyte, Inc. (NASDAQ:ECYT), a leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized therapy, today announced that two posters will be presented on its lead, clinical-stage assets,
View HTML
Toggle Summary Endocyte Reports First Quarter Financial Results and Provides Clinical and Pipeline Update
- Conference Call Today at 8:30 a.m. EDT -
View HTML